Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21547
Abstract: e21547Background: Talimogene laherparepvec (Imlygic or T-VEC) is a first-in-class oncolytic virus that received FDA approval for recurrent unresectable melanoma based on the OPTiM trial. Since its ...
read more here.
Keywords:
talimogene laherparepvec;
experience talimogene;
talimogene;
clinical experience ... See more keywords